Kamada Ltd.  

(Public, TLV:KMDA)   Watch this stock  
Find more results for snake
-59.00 (-2.52%)
Jul 10 - Close
TLV data delayed by 20 mins - Disclaimer
Currency in ILA unless noted
Range 2,281.00 - 2,359.00
52 week 23.10 - 2,359.00
Open 2,343.00
Vol / Avg. 88,216.00/117,226.00
Mkt cap 821.33M*
P/E     -
Div/yield     -
EPS -0.05*
Shares 35.96M
Beta     -
Inst. own     -
Jul 28, 2014
Q2 2014 Kamada Ltd Earnings Release (Estimated) Add to calendar
Jun 19, 2014
Kamada Ltd Annual Shareholders Meeting
Jun 5, 2014
Kamada Ltd at Jefferies Global Healthcare Conference
May 16, 2014
Kamada Top Line Phase 3 Data - Webcast
May 8, 2014
Q1 2014 Kamada Ltd Earnings Release

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -23.67% 0.63%
Operating margin -20.53% 5.24%
EBITD margin - 9.49%
Return on average assets -9.02% 0.39%
Return on average equity -14.08% 0.75%
Employees 299 -
CDP Score - -


7 Sapir St. Kiryat Weizmann Science Park, P.O Box 4081
+972-8-9406472 (Phone)
+972-8-9406473 (Fax)

Website links


Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company�s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Officers and directors

David Tsur President, Chief Executive Officer, Co-Founder
Age: 63
Gil Efron Chief Financial Officer
Age: 47
Avi Baziz Chief Operating Officer
Age: 48
Amir London Senior Vice President - Business Development
Ruth Wolfson Ph.D. Senior Vice President, Quality and Regulatory Affairs
Age: 66
Shabtai Bauer Ph.D. Chief Scientist
Age: 80
Barak Bashari Vice President, Operations and Plant Manager
Shani Dotan Vice President of Human Resources
Amir Yadlin Vice President of Human Resources
Age: 56
Drorit Lew Vice President, Quality, Production Plant
Age: 46